Insider Shareholders with Direct Ownership of Monte Rosa Therapeutics, Inc. (GLUE)
This section provides a comprehensive overview of the insiders with direct ownership of Monte Rosa Therapeutics, Inc. (GLUE). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Monte Rosa Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
New Enterprise Associates 17, L.P.
> 10% Shareholder |
7,692,298 | 0 | 7,692,298 $110 Million | 1 |
Jun 28, 2021
Added 12.01%
|
| 6,515,869 | 2,719,646 | 5,099,336 $73.2 Million | 6 |
Sep 20, 2024
Reduced 18.17%
|
|
|
Markus Warmuth
President & CEO |
218,000 | 15,601 | 618,937 $8.89 Million | 4 |
Jan 07, 2026
Reduced 0.05%
|
|
Filip Janku
Chief Medical Officer |
67,000 | 3,155 | 75,026 $1.08 Million | 3 |
Jan 05, 2026
Reduced 4.04%
|
|
Sharon Townson
Chief Scientific Officer |
71,000 | 3,155 | 67,845 $974,254 | 3 |
Jan 05, 2026
Reduced 4.44%
|
|
Jennifer Champoux
Chief Operating Officer |
65,000 | 2,629 | 62,371 $895,647 | 3 |
Jan 05, 2026
Reduced 4.04%
|
|
Philip Nickson
Chief Business & Legal Officer |
64,000 | 3,155 | 60,845 $873,734 | 3 |
Jan 05, 2026
Reduced 4.93%
|
|
Edmund Dunn
Principal Accounting Officer |
11,850 | 5,918 | 22,693 $325,871 | 5 |
Jan 05, 2026
Reduced 4.38%
|
| 10,000 | 0 | 10,000 $143,600 | 1 |
Mar 24, 2025
Added 50.0%
|
|